Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025
Eli Lilly and Company (NYSE: LLY) opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and captured an analyst upgrade with a higher price target—moves that had LLY trading sharply higher intraday. Reuters+2 Today’s headlines at a glance Why the MeiraGTx move matters The MeiraGTx alliance hands Lilly a potential first‑in‑class therapy for LCA4 that, in a small study, has shown the ability to restore visual function in children born legally blind (regulators are evaluating expedited